Across TCGA pan-cancer cohorts, SUPT20HL2 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated SUPT20HL2 data layer compared with 6 for mutation status.
The strongest signal is observed in uveal melanoma (UVM), where higher SUPT20HL2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUPT20HL2 expression acts as an unfavorable survival marker, although some lineages such as BRCA and PRAD show a favorable association.
UVM, COAD, and CHOL are the cancer types where SUPT20HL2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.